AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31813942 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP Fast/Fuji Coat LC
Number of subjects: 34
Study 29858504 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 51
Study 27240816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Nutritional intervention including exposure to posters and distribution of pamphlets to parents with recipes and information about healthy foods.
Number of subjects: 0
Study 27240816 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention.
Number of subjects: 0
Study 24492628 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage with one chest tube (PD1)
Number of subjects: 108
Study 24492628 — intervention group
Group type: COMPARATOR
Intervention: Postoperative drainage with two chest tubes (PD2)
Number of subjects: 108
Study 22713773 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day) in BEAN1
Number of subjects: 267
Study 22713773 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day) in BEAN2
Number of subjects: 267
Study 22713773 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-soy diet <3 servings/week) in BEAN1
Number of subjects: 267
Study 22713773 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-soy diet <3 servings/week) in BEAN2
Number of subjects: 267
Study 20663148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 18)
Number of subjects: 63
Study 20663148 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-based training (n = 14)
Number of subjects: 63
Study 20663148 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 63
Study 17135583 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic use of antiretroviral therapy (drug conservation group)
Number of subjects: 5472
Study 17135583 — intervention group
Group type: COMPARATOR
Intervention: Continuous use of antiretroviral therapy (viral suppression group)
Number of subjects: 5472
Study 14531495 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest X-ray
Number of subjects: 472
Study 14531495 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous chest X-ray
Number of subjects: 472
Study 10903018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% tenoxicam-impregnated gauze pack
Number of subjects: 80
Study 10903018 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline-impregnated gauze pack
Number of subjects: 80
Study 8835583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of rifampicin
Number of subjects: 0
Study 8835583 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of rifampicin
Number of subjects: 0
Study 1418170 — intervention group
Group type: EXPERIMENTAL
Intervention: Factory noise at 60, 70, and 80 dB (A)
Number of subjects: 16
Study 1418170 — intervention group
Group type: EXPERIMENTAL
Intervention: Construction noise at 60, 70, and 80 dB (A)
Number of subjects: 16
Study 1418170 — intervention group
Group type: COMPARATOR
Intervention: Music at 70 dB (A)
Number of subjects: 16
Study 1418170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound noise at 70 dB (A)
Number of subjects: 16
Study 6386749 — intervention group
Group type: EXPERIMENTAL
Intervention: autogenic relaxation training followed by stress-coping training
Number of subjects: 21
Study 6386749 — intervention group
Group type: COMPARATOR
Intervention: autogenic relaxation training followed by stress-coping training supplemented with thermal feedback
Number of subjects: 21
Study 31359830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract images
Number of subjects: 402
Study 31359830 — intervention group
Group type: COMPARATOR
Intervention: Concrete images
Number of subjects: 402
Study 28126684 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe exchange programs (SEPs) with database linkages
Number of subjects: 235
Study 26328056 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1-FV
Number of subjects: 51
Study 26328056 — intervention group
Group type: COMPARATOR
Intervention: Native extract
Number of subjects: 51
Study 26328056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 23602244 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (37.4 mg of elemental iron daily for 12 weeks)
Number of subjects: 40
Study 23602244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study 21747102 — intervention group
Group type: COMPARATOR
Intervention: No pills
Number of subjects: 719
Study 21747102 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded to placebo
Number of subjects: 719
Study 21747102 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded to echinacea
Number of subjects: 719
Study 21747102 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label echinacea
Number of subjects: 719
Study 21747102 — intervention group
Group type: COMPARATOR
Intervention: Blinded to placebo vs No pills
Number of subjects: 719
Study 21747102 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded to echinacea vs Open-label echinacea
Number of subjects: 719
Study 21747102 — intervention group
Group type: COMPARATOR
Intervention: Subgroup (rated echinacea's effectiveness >50) - Blinded to placebo vs No pills
Number of subjects: 719
Study 19456878 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 146
Study 19456878 — intervention group
Group type: COMPARATOR
Intervention: almotriptan 12.5 mg
Number of subjects: 146
Study 16687642 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach placement
Number of subjects: 49
Study 16687642 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional dental school-based clinical experience)
Number of subjects: 49
Study 15611510 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus paclitaxel 200 mg/m² (AP)
Number of subjects: 200
Study 15611510 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (AC)
Number of subjects: 200
Study 11426769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 98
Study 11426769 — intervention group
Group type: COMPARATOR
Intervention: Porcine heparin
Number of subjects: 98
Study 11426769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine and porcine heparin
Number of subjects: 98
Study 9722808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 100
Study 9722808 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 100
Study 9722808 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 100
Study 7744133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (50 mg/200 mcg) administered BID or TID (n = 177)
Number of subjects: 346
Study 7744133 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac/placebo (50 mg) administered BID or TID (n = 169)
Number of subjects: 346
Study 2607914 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm irrigating fluids (temperature between 25.5 degrees C and 33 degrees C)
Number of subjects: 24
Study 2607914 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature irrigating fluids (temperature between 21.5 and 23 degrees C)
Number of subjects: 24
Study 4936538 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with phenothiazines
Number of subjects: 0
Study 4936538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29570121 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 175
Study 28912193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including smartphone application (EVIDENT II), five heart-healthy walks, and diet education group session for 3 months
Number of subjects: 200
Study 26656911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium Chloride (ACID)
Number of subjects: 8
Study 26656911 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate (PLA)
Number of subjects: 8
Study 22243938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS) 100mL (NaCl 7.5%) twice daily for three days
Number of subjects: 34
Study 22243938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS)
Number of subjects: 34
Study 22243938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21425566 — intervention group
Group type: EXPERIMENTAL
Intervention: CM plus SJZD
Number of subjects: 45
Study 21425566 — intervention group
Group type: COMPARATOR
Intervention: CM alone (Control)
Number of subjects: 45
Study 18838979 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ca diet (2300 mg Ca per d)
Number of subjects: 11
Study 18838979 — intervention group
Group type: COMPARATOR
Intervention: Low-Ca diet (700 mg Ca per d)
Number of subjects: 11
Study 16476409 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD patients with major depression (MD)
Number of subjects: 50
Study 16476409 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD patients without major depression (MD)
Number of subjects: 50
Study 16476409 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 50
Study 16476409 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 50
Study 12705061 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cyclooxygenase-2 inhibitors (e.g., celecoxib, rofecoxib, parecoxib)
Number of subjects: 0
Study 12705061 — intervention group
Group type: COMPARATOR
Intervention: Classic non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)
Number of subjects: 0
Study 12705061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 12705061 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 0
Study 12705061 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 0
Study 11777093 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized balance training programme (experimental group)
Number of subjects: 94
Study 11777093 — intervention group
Group type: COMPARATOR
Intervention: Individualized extra attention programme (control group)
Number of subjects: 94
Study 9253571 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release diclofenac sodium
Number of subjects: 52
Study 9253571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8292679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 19
Study 8292679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT at 2.25 T
Number of subjects: 19
Study 8292679 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT at barely suprathreshold stimuli
Number of subjects: 19
Study 8292679 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage (2.25 T)
Number of subjects: 19
Study 2853164 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular porous hydroxylapatite implants
Number of subjects: 10
Study 2853164 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid porous hydroxylapatite implants
Number of subjects: 10
Study 31490817 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 1 µg/mL (group P1)
Number of subjects: 40
Study 31490817 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 2 µg/mL (group P2)
Number of subjects: 40
Study 31490817 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 3 µg/mL (group P3)
Number of subjects: 40
Study 31490817 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 to 3 µg/mL)
Number of subjects: 40
Study 29788248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1731
Study 29788248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1731
Study 28708421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management
Number of subjects: 858
Study 28708421 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid management
Number of subjects: 858
Study 25200901 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracker software
Number of subjects: 33
Study 25200901 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic format
Number of subjects: 33
Study 22248760 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) before incision
Number of subjects: 29
Study 22248760 — intervention group
Group type: COMPARATOR
Intervention: Saline solution before incision followed by epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) after incision
Number of subjects: 29
Study 22248760 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural S(+)-ketamine
Number of subjects: 29
Study 22248760 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 29
Study 19479454 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC-flakes
Number of subjects: 51
Study 19479454 — intervention group
Group type: COMPARATOR
Intervention: Control cereals
Number of subjects: 51
Study 17487638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders programmed to prompt target behaviours
Number of subjects: 5
Study 16284537 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive HIV vaccine trial
Number of subjects: 363
Study 12190904 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique plus synthetic bioactive resorbable graft (OsteoGen) and GoreTex membrane (Group C)
Number of subjects: 28
Study 12190904 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique plus nonbioabsorbable GoreTex membrane (Group B)
Number of subjects: 28
Study 12190904 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (Group A)
Number of subjects: 28
Study 9789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride, Repaglinide, Glucagon-like peptide I (drugs stimulating insulin secretion)
Number of subjects: 0
Study 9789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (medications reducing insulin resistance)
Number of subjects: 0
Study 9789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadium (insulin-mimetic agents)
Number of subjects: 0
Study 9789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha glucosidase inhibitors
Number of subjects: 0
Study 7542114 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 16
Study 7542114 — intervention group
Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 16
Study 8638061 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocysteine
Number of subjects: 44
Study 8638061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 392832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone
Number of subjects: 20
Study 392832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ATG)
Number of subjects: 20
Study 31924322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg dual therapy
Number of subjects: 2725
Study 31924322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg dual therapy
Number of subjects: 2725
Study 31924322 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran dual therapy
Number of subjects: 2725
Study 31924322 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 2725
Study 30574802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6×10^9 cfu)
Number of subjects: 474
Study 30574802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 474
Study 30574802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 30574802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019 (9×10^9 cfu)
Number of subjects: 474
Study 30574802 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who developed eczema
Number of subjects: 474
Study 25192771 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 112
Study 25192771 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes with lower nicotine yield (0.05 mg)
Number of subjects: 112
Study 25192771 — intervention group
Group type: COMPARATOR
Intervention: Co-use of normal nicotine content cigarettes
Number of subjects: 112
Study 23938046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Number of subjects: 270
Study 23938046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Number of subjects: 270
Study 23938046 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Conservation Management
Number of subjects: 270
Study 23938046 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention (control)
Number of subjects: 270
Study 21333426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445
Study 21333426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study 19341987 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate 15mg/day capsules
Number of subjects: 40
Study 19341987 — intervention group
Group type: COMPARATOR
Intervention: Corn-starch placebo
Number of subjects: 40
Study 17298975 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 826
Study 17298975 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 826
Study 17298975 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) in small stents/bypass grafts
Number of subjects: 826
Study 17298975 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) in other patients
Number of subjects: 826
Study 16329082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh
Number of subjects: 300
Study 16329082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 300
Study 12791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Plywood ceiling
Number of subjects: 0
Study 12791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic-netting ceiling
Number of subjects: 0
Study 12791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated synthetic-netting ceiling (deltamethrin 12.5 mg/m2)
Number of subjects: 0
Study 12791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic insect-screen ceiling
Number of subjects: 0
Study 12791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed eaves with mud
Number of subjects: 0
Study 12791056 — intervention group
Group type: COMPARATOR
Intervention: Control hut
Number of subjects: 0
Study 10522581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg x ml(‐1)
Number of subjects: 104
Study 10522581 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5.0 mg x ml(‐1)
Number of subjects: 104
Study 7794434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block
Number of subjects: 280
Study 7794434 — intervention group
Group type: COMPARATOR
Intervention: femoral nerve block
Number of subjects: 280
Study 1723814 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosine 2.5 mg x 3
Number of subjects: 33
Study 1723814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7048251 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril-labetalol combination treatment
Number of subjects: 15
Study 7048251 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 15
Study 7048251 — intervention group
Group type: COMPARATOR
Intervention: Labetalol alone
Number of subjects: 15
Study 31537504 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography at 70 kVp
Number of subjects: 63
Study 31537504 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy CT with VMI at 40 keV
Number of subjects: 63
Study 31242924 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated risk assessment using HM metascore
Number of subjects: 604
Study 31242924 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival prediction by HM metascore
Number of subjects: 604
Study 28481335 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIMMER combined dietary and physical activity lifestyle intervention (10-month programme)
Number of subjects: 316
Study 28481335 — intervention group
Group type: COMPARATOR
Intervention: Usual healthcare (control group)
Number of subjects: 316
Study 25278227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-valent human papillomavirus vaccine (selected dose formulation)
Number of subjects: 15000
Study 25278227 — intervention group
Group type: COMPARATOR
Intervention: Four-valent human papillomavirus vaccine (active control)
Number of subjects: 15000
Study 25278227 — intervention group
Group type: COMPARATOR
Intervention: Four-valent human papillomavirus vaccine
Number of subjects: 15000
Study 23443238 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day complete dietary replacement (Arm 1)
Number of subjects: 40
Study 23443238 — intervention group
Group type: COMPARATOR
Intervention: Written recommendations to reduce phthalate and BPA exposures (Arm 2)
Number of subjects: 40
Study 21459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Two intensive courses (trial 9801)
Number of subjects: 211
Study 21459791 — intervention group
Group type: EXPERIMENTAL
Intervention: One intensive course (trial 9803)
Number of subjects: 211
Study 21459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Six outpatient courses (trial 9803)
Number of subjects: 211
Study 21459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival after complete remission (planned post-remission courses)
Number of subjects: 211
Study 21459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable or normal karyotype (n=97)
Number of subjects: 211
Study 18645509 — intervention group
Group type: EXPERIMENTAL
Intervention: m-DOT
Number of subjects: 234
Study 16776928 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 ‐ 15 mg before sleep, n = 113)
Number of subjects: 217
Study 16776928 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam (1 ‐ 2 mg before sleep, n = 104)
Number of subjects: 217